CXO enters the performance release period, and a large number of companies have outstanding performance

As of March 28, among the more than ten CXO companies listed in China, 6 companies including WuXi AppTec, WuXi Biologics, Pharmaron, Zhaoyan New Drug, Medicilon, and Proton have released their 2021 annual reports.
Three companies including Yaoshi Technology, Asymchem, and Jiuzhou Pharmaceutical announced their 2021 annual performance forecast report
.
Overall, most companies performed well
.
On March 24, WuXi AppTec released its 2021 performance report, achieving revenue of 22.
902 billion yuan, a year-on-year increase of 38.
50%; net profit attributable to the parent company of 5.
097 billion yuan, a year-on-year increase of 72.
19%
.
The company's performance growth is mainly due to the fact that in 2021, WuXi AppTec will serve more than 5,700 active customers in more than 30 countries around the world through 31 operating bases and branches around the world
.
On March 23, WuXi Biologics released its 2021 performance report, achieving revenue of 10.
29 billion yuan, a year-on-year increase of 83.
3%; net profit attributable to the parent reached 3.
389 billion yuan, a year-on-year increase of 100.
6%
.
The main factor behind the company's 2021 performance surge is that late-stage clinical development services and commercial production contribute most of the revenue
.
On March 10, Pharmaron released its 2021 performance report: revenue was 7.
444 billion yuan, a year-on-year increase of 45%; net profit attributable to the parent was 1.
661 billion yuan, a year-on-year increase of 41.
68%
.
The announcement shows that the company's net profit growth is due to the further growth of the scale effect under the revenue growth
.
On the evening of February 28, Proton announced its 2021 performance report.
In 2021, the company achieved operating income of 3.
105 billion yuan, a year-on-year increase of 49.
87%; net profit attributable to the parent was 524 million yuan, a year-on-year increase of 61.
49%; 503 million yuan, an increase of 74.
42%, and earnings per share of 0.
97 yuan
.
It is understood that during the reporting period, with the continuous enrichment and expansion of customer pipelines and product pipelines, as well as the further improvement of R&D technical capabilities and product delivery capabilities, the company's overall business for the domestic and international markets has achieved sustained and rapid growth.

.
On February 24, Zhaoyan New Drug disclosed its 2021 annual performance report.
The company will achieve operating income of 1.
517 billion yuan in 2021, a year-on-year increase of 40.
99%, and a net profit attributable to the parent of 557 million yuan, a year-on-year increase of 76.
83%
.
It is reported that the company has always strengthened technological innovation, established and standardized the industry's innovative drug evaluation technology platform
.
At the same time, it continued to strengthen the research and development support for innovative drugs and original innovations of new technology platforms.
New orders for the year exceeded 2.
8 billion yuan, and as of the end of the reporting period, orders in hand exceeded 2.
9 billion yuan
.
Medicilon released a performance bulletin on the evening of February 25.
In 2021, the operating income will be 1.
167 billion yuan, a year-on-year increase of 75.
27%; the net profit attributable to the parent is 282 million yuan, a year-on-year increase of 117.
93%; basic earnings per share are 4.
55 yuan
.
During the reporting period, benefiting from the continuous increase in the encouragement of the state’s policies on the pharmaceutical industry and the continuous increase in the investment in innovative drug research and development by pharmaceutical companies, the company has firmly grasped the development opportunities of the pre-clinical CRO market while optimizing its business structure.
The development ability and order acceptance ability were simultaneously improved
.
According to the performance forecast released by Yaoshi Technology on January 26, the company expects a profit of 479 million yuan to 497 million yuan in 2021, an increase of 160%-170% over the same period last year
.
The main reason for the change in performance is that the company has further increased its operating scale by optimizing its revenue structure, improving operating efficiency, and increasing capacity utilization, even though its production capacity has not grown significantly
.
Asymchem released a performance forecast on January 26, predicting that the net profit attributable to the full year of 2021 will be 1.
040 billion yuan to 1.
076 billion yuan, an increase of 44% to 49% over the previous year
.
Mainly due to the strong growth of the small molecule business and the fast-track entry of emerging businesses
.
In addition, according to the performance forecast released by Jiuzhou Pharmaceutical on January 19, it is expected that the net profit in 2021 will reach 609 million yuan to 685 million yuan, a year-on-year increase of 60%-80%
.
This year's performance growth is mainly due to the continuous growth of the company's CDMO business
.
On the whole, the CXO industry has a high degree of prosperity.
Industry analysts believe that in the future, companies with core competitiveness such as technology and integration will become stronger and stronger, and industry resources will be further closer to leading companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.